Verici Dx (LON:VRCI) Shares Climb 9.3% – Still a Buy?

Verici Dx plc (LON:VRCI – Get Free Report)’s stock price traded up 9.3% during trading on Friday. The company traded as high as GBX 0.25 and last traded at GBX 0.23. 56,845,227 shares were traded during mid-day trading, an increase of 1,694% from the average daily volume of 3,169,219 shares. The stock had previously closed at GBX 0.21.

Verici Dx Trading Up 9.3%

The company has a 50 day moving average price of GBX 0.22 and a 200 day moving average price of GBX 0.34. The firm has a market cap of £5.38 million, a price-to-earnings ratio of 2.35 and a beta of 1.22. The company has a debt-to-equity ratio of 13.51, a quick ratio of 8.49 and a current ratio of 2.82.

Verici Dx Company Profile

(Get Free Report)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.

See Also

Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.